Improving the therapeutic index in myeloma

Blood

Volumn 116, Issue 23, 2010, Pages 4733-4734

  Richardson, Paul G ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORON DERIVATIVE; BORTEZOMIB; CARFILZOMIB; LENALIDOMIDE; MELPHALAN; MLN 9708; PREDNISONE; SALINOSPORAMIDE A; THALIDOMIDE; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUROTOXICITY; NOTE; PERIPHERAL NEUROPATHY; POST HOC ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 78649734522     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-10-306373     Document Type: Note

References (10)

1. Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745-4753.
2. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
3. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan-prednisone versus melphalan-prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase 3 VISTA trial. J Clin Oncol. 2010;28(13):2259-2266.
4. Mateos MV, Richardson PG, Schlag R, et al. Peripheral neuropathy with VMP resolves in the majority of patients and shows a rate plateau [abstract]. Clin Lymphoma Myeloma. 2009;9(suppl 1):S30. Abstract A172.
5. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009;27(21):3518-3525.
6. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-3120. (Pubitemid 46638949)
7. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009;27(34):5713-5719.
8. Broyl A, Corthals SL, Jongen JL, et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4trial [published online ahead of print September 21, 2010]. Lancet Oncol. doi:10.1016/S1470-2045(10)70206-0.
9. Niesvizky R, Wang L, Orlowski RZ, et al. The Multiple Myeloma Research Consortium (MMRC). Phase Ib multicenter dose escalation study of carfilzomib plus lenalidomide and low dose dexamethasone (CRd) in relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 304.
10. Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010;115(4):834-845.